Regulatory approval

Published by the Health Service Executive. Approved

Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.

This is written in the approval document.

Reimbursement

Hospital

Citation

(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days, 2024, version number 5a, NCCP National SACT Regimen, viewed 26/03/2026, https://healthservice.hse.ie/documents/6711/307_v5a_R_Chop_21_days.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-01-18	Health Service Executive	Indication approved for reimbursement.